Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million
U.S. RESEARCH ROUNDUP-CNX Resources, P&G, Prologis
Brief: Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering
Trevi Therapeutics falls from record on $150 mln stock sale
Brief: Trevi Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock
Brief: Trevi Therapeutics Announces Proposed Public Offering Of Common Stock
Trevi Therapeutics slides after launching $150 mln stock offering
Trevi Therapeutics Q4 net loss narrows on lower R&D costs
Brief: Trevi Therapeutics Q4 Net Income USD -8.316 Million
Brief: Trevi Therapeutics Provides Strategic Updates Ahead Of Annual Lifesci Partners Corporate Access Event
Brief: Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer
Trevi Therapeutics Q3 net loss narrows, cash runway extended into 2028
Brief: Trevi Therapeutics Q3 Net Income USD -11.802 Million
Brief: Trevi Therapeutics Announces Oral Presentation And Abstracts At Chest 2025 Annual Meeting
Brief: Trevi Therapeutics To Present Two Phase 2a River Trial Posters At ERS Congress 2025
Brief: Trevi Therapeutics Says Lisa Delfini To Resign As CFO On Aug 22